← All countries · Americas
87%
MCV1
2025 · WHO/UNICEF estimate
80%
DTP3
2025 · WHO/UNICEF estimate
80%
IPV complete
2025 · WHO/UNICEF estimate
80%
HepB3
2025 · WHO/UNICEF estimate
0
Measles cases
2025 reported
52
Pertussis (whooping cough) cases
2025 reported
Two kinds of number live on this page. Coverage is the share of the target cohort vaccinated, as estimated by WHO and UNICEF each July from the country's reports, surveys and other evidence, shown beside what the country itself reported. Reported cases are what the national surveillance system sent to WHO; they are a floor, not a count of infections. Every row carries a grade; hover or focus it for the reason, or read how grades are assigned.
Vaccination coverage
| Vaccine | Latest estimate | Country-reported | Trend since 2000 | Data quality |
|---|---|---|---|---|
| BCGTuberculosis vaccine at birth | 99%2025 · WHO/UNICEF estimate | 100% | A · strong | |
| DTP1First dose of diphtheria-tetanus-pertussis | 94%2025 · WHO/UNICEF estimate | 96.4% | B · good | |
| DTP3Third dose of diphtheria-tetanus-pertussis (the WHO benchmark of a working programme) | 80%2025 · WHO/UNICEF estimate | 80.2% | A · strong | |
| IPV1First dose of inactivated polio vaccine | 94%2025 · WHO/UNICEF estimate | 96.4% | B · good | |
| IPV completeInactivated polio vaccine, complete primary series | 80%2025 · WHO/UNICEF estimate | 80.2% | C · weak | |
| MCV1First dose of measles-containing vaccine | 87%2025 · WHO/UNICEF estimate | 90.6% | B · good | |
| MCV2Second dose of measles-containing vaccine | 85%2025 · WHO/UNICEF estimate | 60.8% | B · good | |
| RCV1First dose of rubella-containing vaccine | 87%2025 · WHO/UNICEF estimate | 90.6% | B · good | |
| HepB3Third dose of hepatitis B vaccine | 80%2025 · WHO/UNICEF estimate | 80.2% | A · strong | |
| HepB birthHepatitis B birth dose within 24 hours | 92%2025 · WHO/UNICEF estimate | 91.6% | A · strong | |
| Hib3Third dose of Haemophilus influenzae type b vaccine | 80%2025 · WHO/UNICEF estimate | 80.2% | A · strong | |
| PCV1Pneumococcal conjugate vaccine, first dose | 95.9%2025 · Administrative (country-reported) | 95.9% | D · poor | |
| PCV completePneumococcal conjugate vaccine, final dose of the schedule | 77%2025 · WHO/UNICEF estimate | 81.7% | A · strong | |
| RotaCRotavirus vaccine, complete series | 87%2025 · WHO/UNICEF estimate | 88.8% | A · strong | |
| Yellow feverYellow fever vaccine (countries at risk) | 5%2025 · WHO/UNICEF estimate | 92.3% | D · poor | |
| MenAMeningococcal A conjugate (meningitis belt) | —% · Administrative (country-reported) | — | too few points | no data |
| JEJapanese encephalitis vaccine (countries at risk) | —% · Administrative (country-reported) | — | too few points | no data |
| TCVTyphoid conjugate vaccine | —% · Administrative (country-reported) | — | too few points | no data |
| PABProtection at birth against neonatal tetanus (maternal tetanus doses) | 89.5%2025 · Administrative (country-reported) | 89.5% | D · poor | |
| HPV dose 1, girlsHPV programme coverage, first dose, girls | 81%2025 · WHO/UNICEF estimate | — | B · good | |
| HPV complete, girlsHPV programme coverage, complete series, girls | 70%2025 · WHO/UNICEF estimate | — | B · good | |
| HPV dose 1, boysHPV programme coverage, first dose, boys | 73%2025 · WHO/UNICEF estimate | — | B · good |
Reported vaccine-preventable disease
| Disease | Reported cases | Incidence rate | Trend since 2000 | Data quality |
|---|---|---|---|---|
| Measles all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | C · weak | |
| Rubella all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | C · weak | |
| Congenital rubella syndrome all countries · vaccine evidence | 02025 | 0per 10,000 live births | B · good | |
| Mumps all countries · vaccine evidence | 162025 | 3.5per 1,000,000 total population | A · strong | |
| Pertussis (whooping cough) all countries · vaccine evidence | 522025 | 11.4per 1,000,000 total population | A · strong | |
| Diphtheria all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | B · good | |
| Tetanus (total) all countries · vaccine evidence | 12025 | 0.2per 1,000,000 total population | A · strong | |
| Neonatal tetanus all countries · vaccine evidence | 12025 | 0per 1,000 live births | A · strong | |
| Polio (paralytic) all countries · vaccine evidence | 02025 | 0per 1,000,000 <15 population | B · good | |
| Yellow fever all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | C · weak | |
| Japanese encephalitis all countries · vaccine evidence | 02006 | 0per 1,000,000 total population | too few points | no data |
| Invasive meningococcal disease all countries · vaccine evidence | 32025 | 0.7per 1,000,000 total population | C · weak | |
| Typhoid all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | B · good |
National schedule (latest WHO listing)
Show the schedule (72 rows)
| Vaccine | Dose | Age | Target group | Comment |
|---|---|---|---|---|
| BCGBCG (Baccille Calmette Guérin) vaccine | 1 | B | General/routine | <15 años |
| COVID19COVID-19 vaccine | 1 | Adults | All adults, all older adults | |
| COVID19COVID-19 vaccine | 1 | General/routine | All children and adolescents | |
| COVID19COVID-19 vaccine | 1 | Health workers | Health and care workers | |
| COVID19COVID-19 vaccine | 1 | Pregnant women | Pregnant women | |
| COVID19COVID-19 vaccine | 1 | Risk group(s) | Children and adolescents with chronic conditions, adults with chronic conditions, older adults with chronic conditions, other groups | |
| DTAPHIBHEPBIPVDTaP-Hib-HepB-IPV (acellular) vaccine | 1 | M2 | General/routine | |
| DTAPHIBHEPBIPVDTaP-Hib-HepB-IPV (acellular) vaccine | 2 | M4 | General/routine | |
| DTAPHIBHEPBIPVDTaP-Hib-HepB-IPV (acellular) vaccine | 3 | M6 | General/routine | |
| DTAPHIBHEPBIPVDTaP-Hib-HepB-IPV (acellular) vaccine | 4 | M18 | General/routine | |
| DTAPIPVDTaP-IPV (acellular) vaccine | 5 | Y4 | General/routine | |
| HEPA_ADULTAdult Hepatitis A (HepA) vaccine | 1 | >=Y19 | Health workers | > 19 AÑOS,MANIPULADORES DE ALIMENTOS, FUNC. DE SALUD.RECOLECTORES DE BASURA Y DESECHOS PELIGROSOS. |
| HEPA_ADULTAdult Hepatitis A (HepA) vaccine | 1 | >=Y19 | Risk group(s) | > 19 AÑOS,MANIPULADORES DE ALIMENTOS, FUNC. DE SALUD.RECOLECTORES DE BASURA Y DESECHOS PELIGROSOS. |
| HEPA_PEDIATRICPediatric Hepatitis A (HepA) vaccine | 1 | M12 | General/routine | |
| HEPA_PEDIATRICPediatric Hepatitis A (HepA) vaccine | 2 | M18 | General/routine | |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 1 | 1st contact | Health workers | MANIPULADORES DE ALIMENTOS, FUNC, DE SALUD, TRABAJADORAS DEL SEXO COMERCIAL |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 1 | 1st contact | Risk group(s) | MANIPULADORES DE ALIMENTOS, FUNC, DE SALUD, TRABAJADORAS DEL SEXO COMERCIAL |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 2 | +M1 | Health workers | MANIPULADORES DE ALIMENTOS, FUNC, DE SALUD, TRABAJADORAS DEL SEXO COMERCIAL |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 2 | +M1 | Risk group(s) | MANIPULADORES DE ALIMENTOS, FUNC, DE SALUD, TRABAJADORAS DEL SEXO COMERCIAL |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 3 | +M6 | Health workers | MANIPULADORES DE ALIMENTOS, FUNC, DE SALUD, TRABAJADORAS DEL SEXO COMERCIAL |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 3 | +M6 | Risk group(s) | MANIPULADORES DE ALIMENTOS, FUNC, DE SALUD, TRABAJADORAS DEL SEXO COMERCIAL |
| HEPB_PEDIATRICPediatric Hepatitis B (HepB) vaccine | 1 | B | General/routine | RN PRIMERAS 12 HORAS - La vacuna de hepatitis b en recién nacidos es hasta las 12 horas de vida y en casos de partos fortuitos se podrá aplicar hasta las 24 horas. |
| HPV9HPV-9 (Human papillomavirus 9-valent) vaccine | 1 | Y10 | HPV administered to females and males | Niños y niñas de 10 años |
| HPV9HPV-9 (Human papillomavirus 9-valent) vaccine | 1 | >Y15 | Risk group(s) | Víctimas de agresión sexual a partir de los 10 años, pacientes VIH recluídos en clínica retroviral |
| HPV9HPV-9 (Human papillomavirus 9-valent) vaccine | 2 | +M6 | HPV administered to females and males | Niños y niñas de 10 años |
| HPV9HPV-9 (Human papillomavirus 9-valent) vaccine | 2 | +M2 | Risk group(s) | Víctimas de agresión sexual a partir de los 10 años, pacientes VIH recluídos en clínica retroviral |
| HPV9HPV-9 (Human papillomavirus 9-valent) vaccine | 3 | +M6 | Risk group(s) | Víctimas de agresión sexual a partir de los 10 años, pacientes VIH recluídos en clínica retroviral |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | >Y18 | Adults | and older persons >Y60 |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Health workers | Health and care workers | |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Pregnant women | Pregnant women | |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Risk group(s) | Adults with chronic conditions, residents living in long-term care facilities, other groups | |
| INFLUENZA_PEDIATRICPediatric seasonal influenza vaccine | 1 | >=M6 | General/routine | |
| INFLUENZA_PEDIATRICPediatric seasonal influenza vaccine | 1 | Risk group(s) | Children with chronic conditions | |
| MEN_ACYW_135CONJMeningococcal ACYW conjugate vaccine | 1 | >Y1 | Risk group(s) | UNA DOSIS,SOLO MANEJO DE BROTES |
| MMRMMR (Measles, mumps and rubella) vaccine | 1 | M12 | General/routine | Hasta los 19 años |
| MMRMMR (Measles, mumps and rubella) vaccine | 2 | M18 | General/routine | Hasta los 19 años |
| MPOXMpox (monkeypox) vaccine | 1 | 1st contact | Risk group(s) | Pacientes que tengan conductas sexuales de riesgo y contactos de pacientes positivos |
| MPOXMpox (monkeypox) vaccine | 2 | +M1 | Risk group(s) | Pacientes que tengan conductas sexuales de riesgo y contactos de pacientes positivos |
| MRMR (Measles and rubella) vaccine | 1 | >Y19 | Adults | Mayores de 19 años, puérperas, MEF |
| MRMR (Measles and rubella) vaccine | 1 | >Y19 | Risk group(s) | Mayores de 19 años, puérperas, MEF |
| PCV20PCV-20 (Pneumococcal conjugate vaccine 20-valent) vaccine | 1 | >Y60 | Adults | >Mayores de 60 AÑOS, Pacientes con enfermedades crónicas |
| PCV20PCV-20 (Pneumococcal conjugate vaccine 20-valent) vaccine | 1 | M2 | General/routine | Niños menores de 1 año y niños de 1 año |
| PCV20PCV-20 (Pneumococcal conjugate vaccine 20-valent) vaccine | 1 | Risk group(s) | >Mayores de 60 AÑOS, Pacientes con enfermedades crónicas | |
| PCV20PCV-20 (Pneumococcal conjugate vaccine 20-valent) vaccine | 2 | M4 | General/routine | Niños menores de 1 año y niños de 1 año |
| PCV20PCV-20 (Pneumococcal conjugate vaccine 20-valent) vaccine | 3 | Y1 | General/routine | Niños menores de 1 año y niños de 1 año |
| RABIESRabies vaccine | 1 | 1st contact | Risk group(s) | Pre Exposición |
| RABIESRabies vaccine | 2 | +D7 | Risk group(s) | Pre Exposición |
| RABIESRabies vaccine | 3 | +D28 | Risk group(s) | Pre Exposición |
| RABIESRabies vaccine | 4 | +Y1 | Risk group(s) | Pre Exposición |
| ROTAVIRUS_1RV-1 (Rotavirus 1-valent) vaccine | 1 | M2 | General/routine | |
| ROTAVIRUS_1RV-1 (Rotavirus 1-valent) vaccine | 2 | M4 | General/routine | |
| RSVRSV (Respiratory syncytial virus) vaccine | 1 | >Y60 | Adults | Embarazada a partir de la 30 semanas, mayores de 60 años y Pacientes Inmunosuprimidos |
| RSVRSV (Respiratory syncytial virus) vaccine | 1 | Pregnant women | Embarazada a partir de la 30 semanas, mayores de 60 años y Pacientes Inmunosuprimidos | |
| RSVRSV (Respiratory syncytial virus) vaccine | 1 | Risk group(s) | Embarazada a partir de la 30 semanas, mayores de 60 años y Pacientes Inmunosuprimidos | |
| TDAP_STdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine | 1 | Adults | Emb, pareja, cuidadores, adultos mayores, puérperas, población de 4-64 años en el perifoco de casos sospechosos de tosferina | |
| TDAP_STdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine | 1 | Pregnant women | Emb, pareja, cuidadores, adultos mayores, puérperas, población de 4-64 años en el perifoco de casos sospechosos de tosferina | |
| TDAP_STdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine | 1 | Y4-Y64 | Risk group(s) | Emb, pareja, cuidadores, adultos mayores, puérperas, población de 4-64 años en el perifoco de casos sospechosos de tosferina |
| TDAP_STdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine | 6 | Y10 | General/routine | niños y niñas 10 años |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 1 | 1st contact | Adults | Embarazada Y ADULTOS ETC DOS DOSIS Y UN REF |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 1 | Pregnant women | Embarazada Y ADULTOS ETC DOS DOSIS Y UN REF | |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 2 | +M1 | Adults | Embarazada Y ADULTOS ETC DOS DOSIS Y UN REF |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 3 | +Y1 | Adults | Embarazada Y ADULTOS ETC DOS DOSIS Y UN REF |
| VARICELLAVaricella vaccine | 1 | M15 | General/routine | |
| VARICELLAVaricella vaccine | 2 | Y4 | General/routine | |
| VITAMINAVitamin A supplements | 1 | M6 | General/routine | |
| VITAMINAVitamin A supplements | 2 | M12 | General/routine | |
| VITAMINAVitamin A supplements | 3 | M18 | General/routine | |
| VITAMINAVitamin A supplements | 4 | M24 | General/routine | |
| VITAMINAVitamin A supplements | 5 | M30 | General/routine | |
| VITAMINAVitamin A supplements | 6 | M36 | General/routine | |
| YFYF (Yellow fever) vaccine | 1 | Y1 | General/routine · SUBNATIONAL | SOLO EN 3 REGIONES Y A NIVEL DE VACUNACION INTERNACIONAL |
| YFYF (Yellow fever) vaccine | 1 | Travellers | SOLO EN 3 REGIONES Y A NIVEL DE VACUNACION INTERNACIONAL |
Compare schedules across 31 countries on the schedule hub.
Data and sources
- Download this country's data (JSON): every year, every antigen and disease, with the grade reasons.
- Coverage: WHO/UNICEF Estimates of National Immunization Coverage (WUENIC) and country-reported administrative/official coverage, from the WHO Immunization Data Portal export downloaded 21 October 2026.
- Reported cases and incidence: WHO/UNICEF Joint Reporting Form, same export. Incidence denominators are stated per row.
- Schedule: WHO vaccine-schedule export, latest listing year.